Minor injury: 24 weeks at 250500 mcg/day Severe injury or surgery: 46 weeks, up to 1,000 mcg/day Gut repair: 46 weeks oral or SubQ Neurological support: 48 weeks Most patients notice improvements within 710 days, especially in pain reduction and mobility
It supports the development of the brain and the entire nervous system
Not enough folate can cause megaloblastic anemia
Deficiency is also particularly common in elderly people, as the ability to absorb B12 decreases with age
In one study done by Mattson, individuals that intermittent fasted not only lost weigh, but also experienced reductions in markers of oxidative stress, inflammation, and other health and quality of life indicators
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
